PolyPid Begins Phase III PXL01 Trial After Q1 Net Loss of $9.4M
PolyPid reported a Q1 net loss of $9.4M on zero revenue and ended March with $38.1M cash, following a $20M April equity raise. Management commenced a Phase III trial for its PXL01 analgesic patch and struck a distribution pact in Europe.
1. Q1 Financial Performance
PolyPid posted a Q1 net loss of $9.4 million on zero product revenue and ended March 31 with $38.1 million in cash and equivalents. The company bolstered its balance sheet with a $20 million equity financing in April, extending its operational runway into mid-2027.
2. Phase III Trial Launch
In May, PolyPid initiated a multicenter Phase III trial of its PXL01 bioadhesive patch for post-surgical pain management, targeting enrollment of 300 patients across 20 U.S. sites. The study’s primary endpoints include reduction in pain scores and opioid use through 14 days post-procedure.
3. European Distribution Agreement
PolyPid entered a distribution partnership with VegaPharm to commercialize PXL01 in key European markets upon approval. The agreement grants VegaPharm exclusive rights in Germany, France and the UK, with launch anticipated in 2028 pending regulatory clearance.